openPR Logo
Press release

Investigation announced for Investors in shares of Moderna, Inc. (NASDAQ: MRNA) over possible Violations of Securities Laws

05-27-2020 08:24 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Moderna, Inc. (NASDAQ: MRNA) shares over potential securities laws violations by Moderna, Inc..

An investigation for investors in Moderna, Inc. (NASDAQ: MRNA) shares over potential securities laws violations by Moderna, Inc..

An investigation was announced for investors of Moderna, Inc. (NASDAQ: MRNA) shares over potential securities laws violations by Moderna, Inc. in connection with certain financial.

Investors who purchased shares of Moderna, Inc. (NASDAQ: MRNA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Moderna, Inc. (NASDAQ: MRNA) concerning whether a series of statements by Moderna, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

On May 18, 2020, Moderna, Inc a announced Phase 1 trial results for a candidate vaccine for COVID-19 under development by the Company, indicating that the candidate appeared to generate an immune response similar to the response seen in individuals who have been infected by the virus and recovered. Specifically, Moderna reported that eight patients who received two doses of the vaccine at the lowest and middle doses tested - 25 and 100 micrograms - developed neutralizing antibodies to the virus at levels similar to people who had recovered from infection.

Shares of Moderna, Inc. (NASDAQ: MRNA) rose to $87.00 per share on May 18, 2020.

In the days following Moderna's announcement, the Company's announcement was the subject of skeptical commentary from multiple sources. For example, on May 19, 2020, an article was published entitled "Vaccine experts say Moderna didn't produce data critical to assessing Covid-19 vaccine," which noted, in part, that "[w]hile Moderna blitzed the media, it revealed very little information - and most of what it did disclose were words, not data."

Shares of Moderna, Inc. (NASDAQ: MRNA) declined to $57.05 per share on May 26, 2020.

Those who purchased shares of Moderna, Inc. (NASDAQ: MRNA) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Moderna, Inc. (NASDAQ: MRNA) over possible Violations of Securities Laws here

News-ID: 2059886 • Views: 716

More Releases from Shareholders Foundation

ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) Investor Alert: Deadline in …
A deadline is coming up on September 28, 2020 in the lawsuit filed for certain investors of ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) over alleged securities laws violations. Investors who purchased shares of ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) have certain options and there are strict and short deadlines running. Deadline: September 28, 2020. NYSEArca: UCO stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation announced for Long-Term Investors in shares of Forescout Technolog …
An investigation was announced for long-term investors in shares of Forescout Technologies, Inc. (NASDAQ: FSCT) concerning potential breaches of fiduciary duties by certain directors and officers of Forescout Technologies, Inc.. Investors who are current long term investors in Forescout Technologies, Inc. (NASDAQ: FSCT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ:
Investigation announced for Long-Term Investors in shares of Hebron Technology C …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Hebron Technology Co., Ltd.. Investors who are current long term investors in Hebron Technology Co., Ltd. (NASDAQ: HEBT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: HEBT stocks follows a lawsuit filed against Hebron
Investigation announced for Investors in shares of CrossFirst Bankshares, Inc. ( …
An investigation was announced concerning potential securities laws violations by CrossFirst Bankshares, Inc. in connection with certain financial statements. Investors who purchased shares of CrossFirst Bankshares, Inc. (NASDAQ: CFB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether certain statements by CrossFirst Bankshares, Inc. regarding its business, its prospects and its operations were materially false

All 5 Releases


More Releases for Moderna

mRNA Vaccine Market Competitive Share & Forecast 2019| Moderna Therapeutics, Cur …
The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global mRNA Vaccine market. It sheds light on how the global mRNA Vaccine Market is expected to grow during the course of the forecast period. With SWOT analysis and Porter’s Five Forces analysis, it gives a deep explanation of the strengths and weaknesses of the global mRNA Vaccine market and different
Global mRNA Cancer Vaccines and Therapeutics Market to 2025| Moderna Therapeutic …
Researchmoz added Most up-to-date research on "Global mRNA Cancer Vaccines and Therapeutics Market Size, Status and Forecast 2019-2025" to its huge collection of research reports. mRNA Cancer Vaccines and Therapeutics Market report includes (6 Year Forecast 2019-2025) includes Overview, classification, industry value, price, cost and gross profit. It also offers in-intensity insight of the mRNA Cancer Vaccines and Therapeutics industry masking all vital parameters along with, Drivers, Market Trends, Market Dynamics,
mRNA Vaccine Market Professional Analysis Report 2019| Moderna Therapeutics, Cur …
Los Angeles, United State, Mar 5, 2019-The research report focuses on target groups of customers to help players to effectively market their products and achieve strong sales in the global mRNA Vaccine market. It segregates useful and relevant market information as per the business needs of players. Readers are provided with validated and revalidated market forecast figures such as CAGR, mRNA Vaccine market revenue, production, consumption, and market share. Our
MRNA Vaccines & Therapeutics Market 2019 Global Analysis By Key Players – Mode …
WiseGuyReports.Com Publish a New Market Research Report On –“ MRNA Vaccines & Therapeutics Market 2019 Global Analysis By Key Players – Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics”. Description:- The mRNA Vaccines & Therapeutics industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, mRNA Vaccines & Therapeutics market size to maintain the average annual growth rate of XXX from
New Research Study on mRNA Vaccines & Therapeutics Market: Key Players involved …
A new research document is added in HTF MI database of 116 pages, titled as 'Global mRNA Vaccines & Therapeutics Market Report 2018 ' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy), Other
MRNA Vaccines & Therapeutics Market Global Analysis On Top Key Players - Moderna …
Market Study Report recently introduced new title on “2018-2023 Global MRNA Vaccines & Therapeutics Market Report” from its database. The report provides study with in-depth overview, describing about the Product, Industry Scope and elaborates market outlook and status to 2023. The research of mRNA Vaccines & Therapeutics to treat infectious disease, cancer and others. The expenses on infectious disease is the most, with the market share of 46% in 2017.Over the